FGFR1 and small cell lung carcinoma: Although one major exception for this scenario is FGFR amplification that is observed in 6% of SCLC cases (Peifer et al., 2012; George et al., 2015) and is anticipated to activate the MAPK pathway, another recent study showed that FGFR1 is disadvantageous for the development of typical central SCLC with NE differentiation using a Rb1flox/flox;Trp53flox/flox;LSL-Fgfr1K656E mouse model (Ferone et al., 2020).